Medical Oncologist
Third-generation EGFR inhibitor
How Does Osimertinib Work? — The EGFR Pathway Explained
Osimertinib was prescribed because your tumour carries a specific genetic change that drives its growth. This page explains what that change is, why this drug is designed to target it, and what taking it is like in practice.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- A precise target — Osimertinib blocks a single faulty protein, not cancer cells generally.
- Built for brain penetration — Unlike older EGFR drugs, it is designed to reach cancer cells that have spread into the brain.
- Resistance was expected — It was developed specifically to overcome the T790M resistance mutation that older EGFR drugs could not handle.
- Not chemotherapy — The side effect profile is different from chemotherapy because the mechanism is entirely different.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Osimertinib is a third-generation EGFR inhibitor. It works by locking onto a faulty EGFR protein inside cancer cells that carries a specific mutation, switching off the signal that tells those cells to grow and divide. Unlike older EGFR drugs, it is also designed to cross into the brain, where lung cancer sometimes spreads.
What does osimertinib actually target inside a cancer cell?
Osimertinib targets a protein called EGFR — specifically, a mutated form of it that sits on the surface of lung cancer cells and sends a permanent signal for the cell to grow. In healthy tissue, EGFR switches on briefly when needed and then switches off; in these cancers, the mutation keeps it permanently active.
Osimertinib works by binding directly and tightly to the mutated EGFR protein, blocking it from sending that grow signal. Once the protein is blocked, the cancer cell loses the main instruction telling it to divide.
This only works when your tumour carries the specific EGFR mutation the drug is designed for. That is why your oncologist tested your tumour tissue before recommending it — the mutation in the test report is the target this drug was built to hit.
What will your team have confirmed before you start?
- Your tumour tissue has been tested and confirmed to carry an EGFR mutation — most commonly an exon 19 deletion or an exon 21 L858R substitution
- Your diagnosis is non-small cell lung cancer (NSCLC)
- Other medicines you take have been reviewed, because some can affect how osimertinib works in the body
- A baseline heart tracing (ECG) may have been taken before your first dose
- You have been told how and when to take the tablet, and what to do if you miss one
What do these terms mean?
- EGFR
- Epidermal growth factor receptor — a protein on the surface of cells that tells them when to grow. A mutation in the gene that makes this protein can cause it to stay permanently switched on in cancer cells.
- EGFR mutation
- A change in the DNA instructions for making the EGFR protein. This change is what makes the protein behave abnormally and drive cancer growth, and it is the change osimertinib is designed to block.
- Exon 19 deletion / exon 21 L858R
- The two most common EGFR mutations in lung cancer. Both keep EGFR permanently active. Osimertinib is approved for both as a first-line treatment.
- T790M
- A secondary resistance mutation that some cancer cells develop after being treated with first or second-generation EGFR inhibitors. Osimertinib was specifically designed to target this mutation.
- Tyrosine kinase inhibitor (TKI)
- The drug class osimertinib belongs to. TKIs work by blocking specific signalling proteins inside cells — in this case, the mutated EGFR protein.
- Blood-brain barrier
- A tight filter between the bloodstream and the brain that protects the brain but also keeps out many medicines. Osimertinib is formulated to cross this barrier more effectively than earlier EGFR drugs.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Why is osimertinib different from older EGFR drugs?
Osimertinib overcomes two limitations that reduced the long-term effectiveness of first and second-generation EGFR inhibitors: resistance to a mutation called T790M, and limited penetration of the brain.
Earlier EGFR drugs stopped working in many patients when tumour cells developed the T790M mutation. Osimertinib was designed from the start to target this resistance mutation, which is why it is used both as a first-line treatment and when earlier EGFR therapy has failed and T790M has been confirmed.
On brain penetration, NCCN and ESMO guidelines both recognise that osimertinib's ability to cross the blood-brain barrier gives it an advantage over earlier EGFR inhibitors for disease that has spread or is at risk of spreading to the brain.
What is it like to take osimertinib day to day?
Osimertinib is taken as a tablet by mouth, with or without food. Your oncologist or pharmacist will confirm the dosing schedule and what to do if you vomit shortly after a dose or miss a day entirely.
The most common side effects to be aware of are skin changes — rash, dryness, soreness around the fingernails — and loose motions. Most people find these manageable, and your team has ways to help if they affect your daily life.
Follow-up scans will be arranged to assess how the cancer is responding. Between appointments, tell your team promptly if you develop new breathlessness, a persistent dry cough, or chest symptoms — these are not typical side effects and need to be assessed the same day.
What else do people ask about osimertinib?
Tagrisso is written on my prescription — is that the same as osimertinib?
Yes. Tagrisso is the brand name and osimertinib is the generic (chemical) name for exactly the same medicine. Your prescription, packaging, or infusion documentation may use either name or both. If you ever see a different name on packaging from a different supplier, ask your pharmacist to confirm it is the same molecule before taking it — and let your oncology team know that the supplier has changed.
Does osimertinib crossing the blood-brain barrier mean my cancer has already spread to my brain?
No. The blood-brain barrier crossing is a property of the drug — it means the medicine is able to reach the brain if cancer cells are ever present there. It says nothing about whether your cancer has spread to your brain right now. Your oncologist will tell you what your scans show about the current state of your disease. If you are unsure what your scan results mean, ask your team to walk you through them at your next appointment.
Which side effects need a same-day call?
Call your team the same day if you develop new or worsening breathlessness, a persistent dry cough, chest pain, or a rapid or irregular heartbeat. These can be signs of lung inflammation or a heart effect — uncommon, but important to assess without delay. A fever alongside any symptom also needs same-day contact. Skin rash, mild diarrhoea, and tiredness are common and usually manageable; mention these at your next scheduled visit rather than waiting until they become severe.
How will we know if osimertinib is working?
Your team will arrange CT or PET-CT scans at intervals to compare the tumour against your baseline imaging. Some patients see clear shrinkage; others see the disease stabilise without shrinking — both can represent a meaningful response depending on the cancer's behaviour. You do not need to notice a symptom change to confirm the drug is working. Response is typically assessed after a number of weeks of treatment, at a point your oncologist will tell you in advance.
What happens if osimertinib eventually stops working?
Over time, cancer cells can develop new changes that allow them to grow despite the drug. When this happens, your oncologist may arrange a repeat tissue biopsy or a liquid biopsy — a blood test that looks for cancer DNA — to identify the resistance mechanism. Treatment options at that point depend on what resistance is found and what is approved at the time. NCCN and ESMO guidance in this area continues to evolve, and clinical trials may be an option worth discussing with your team.
Can I take herbal medicines or supplements alongside osimertinib?
Some herbal preparations and supplements can affect the way osimertinib is processed by the liver, which may make it work less well or increase side effects. This includes certain traditional Indian preparations, grapefruit products, and preparations containing St John's Wort. The safest approach is to give your treating team a full list of everything you are taking — prescription, over-the-counter, and herbal — before starting and whenever anything changes. This is standard caution for any medicine the liver processes, not a judgement on traditional practice.
Explore 75 more Lung Cancer Targeted Medicines topics
Drug Deep Dive: Osimertinib (Tagrisso)
- Adjuvant Osimertinib After Lung Cancer Surgery: Three Years of Tablets
- Breathlessness or New Cough on Osimertinib: Recognising Lung Injury (ILD)
- Diet and Nutrition While on Osimertinib
- Drug, Food and Supplement Interactions With Osimertinib
- Fertility, Pregnancy and Contraception on Osimertinib
- Heart Rhythm and Ejection Fraction Changes on Osimertinib
- How Does Osimertinib Work? The Third-Generation EGFR Inhibitor Explained
- How Long Does Osimertinib Take to Work?
- How Long Will You Stay on Osimertinib?
- Osimertinib (Tagrisso): The Complete Patient Guide
- Osimertinib Myths: Clear Scans, Stopping Early and Generic Quality
- Osimertinib Price in India: Brand, Generic and Monthly Cost
- Osimertinib Side Effects: The Complete List and Timeline
- Osimertinib Success Rate and Survival: An Honest Look at the Numbers
- Osimertinib With Chemotherapy: Who Actually Benefits From the Combination?
- Osimertinib and Brain Metastases: Why It Works Inside the Brain
- Osimertinib in Elderly Patients and Those With Other Illnesses
- Osimertinib vs Gefitinib and Erlotinib: Is the Costlier Drug Worth It?
- Rash, Dry Skin and Nail Problems on Osimertinib
- Taking Osimertinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Osimertinib
- When Osimertinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Osimertinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Osimertinib?
- Work, Travel and Daily Life on Osimertinib
Drug Deep Dive: Alectinib (Alecensa)
- Alectinib (Alecensa, Alectinib): The Complete Patient Guide
- Alectinib After Surgery for Early-Stage ALK-Positive Lung Cancer
- Alectinib Myths: Is ALK-Positive Cancer 'Curable'?
- Alectinib Price in India: Brand, Generic and Monthly Cost
- Alectinib Side Effects: The Complete List and Timeline
- Alectinib Success Rate and Survival: An Honest Look at the Numbers
- Alectinib and Brain Metastases: How It Protects the Brain
- Alectinib in Elderly Patients and Those With Other Illnesses
- Alectinib vs Crizotinib vs Lorlatinib: Choosing an ALK Inhibitor
- Diet and Nutrition While on Alectinib
- Do You Need Chemotherapy Alongside Alectinib?
- Drug, Food and Supplement Interactions With Alectinib
- Fertility, Pregnancy and Contraception on Alectinib
- How Does Alectinib Work? The Second-Generation ALK Inhibitor Explained
- How Long Does Alectinib Take to Work?
- How Long Will You Stay on Alectinib?
- Muscle Pain and High CPK on Alectinib: When to Worry
- Severe Sun Sensitivity on Alectinib: Preventing Serious Burns
- Taking Alectinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Alectinib
- Weight Gain, Constipation and a Slow Pulse on Alectinib
- When Alectinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Alectinib? ALK-Positive Lung Cancer
- Will Insurance or a Government Scheme Pay for Alectinib?
- Work, Travel and Daily Life on Alectinib
Drug Deep Dive: Gefitinib (Iressa)
- Diarrhoea on Gefitinib: Home Management and Warning Signs
- Diet and Nutrition While on Gefitinib
- Fertility, Pregnancy and Contraception on Gefitinib
- Gefitinib (Iressa, Geftinat, Geftib): The Complete Patient Guide
- Gefitinib Myths: 'It's Only for Poor Patients' and Other Half-Truths
- Gefitinib Plus Chemotherapy: Does Adding Chemo Actually Help?
- Gefitinib Price in India: Brand, Generic and Monthly Cost
- Gefitinib Rash: Why It Appears in Week Two and How to Treat It
- Gefitinib Side Effects: The Complete List and Timeline
- Gefitinib Success Rate and Survival: An Honest Look at the Numbers
- Gefitinib and Antacids: The Interaction That Silently Reduces Absorption
- Gefitinib in Early-Stage vs Advanced Lung Cancer: Different Goals
- Gefitinib in Elderly Patients and Those With Other Illnesses
- Gefitinib vs Osimertinib: Making the Decision When Cost Matters
- How Does Gefitinib Work? The First-Generation EGFR Inhibitor Explained
- How Long Does Gefitinib Take to Work?
- How Long Will You Stay on Gefitinib?
- Raised Liver Enzymes on Gefitinib: What Your LFT Report Means
- T790M Testing After Gefitinib Stops Working: The Next Step Explained
- Taking Gefitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Gefitinib
- When Gefitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Gefitinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Gefitinib?
- Work, Travel and Daily Life on Gefitinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What EGFR mutations does osimertinib treat?
Osimertinib is approved for non-small cell lung cancer carrying an exon 19 deletion or an exon 21 L858R mutation, used as a first treatment before any other systemic therapy. It is also used when a tumour on an older EGFR drug has developed a T790M resistance mutation. Your oncologist will have confirmed which mutation your tumour carries from your tissue test report. If you have not seen that report, ask for a copy — understanding your mutation helps you follow the conversation at appointments.
Is osimertinib the same as chemotherapy?
No. Osimertinib is a targeted therapy, not chemotherapy. Chemotherapy damages all rapidly dividing cells throughout the body, which is why it typically causes significant hair loss and nausea. Osimertinib specifically blocks the mutated EGFR protein driving your cancer, so its side effect profile is different. It has its own side effects — particularly skin changes and, rarely, lung or heart effects — but it is a different class of medicine with a different way of working.
Will I lose my hair on osimertinib?
Significant hair loss is not expected on osimertinib. Hair loss is most associated with chemotherapy, which targets all rapidly dividing cells throughout the body. Some people on osimertinib notice mild changes in hair texture or slight thinning, but the extent of hair loss associated with intravenous chemotherapy is not typical. If you do notice unexpected or significant hair changes, mention them at your next appointment so your team can assess whether they are related to the medicine.
Can I work and travel while taking osimertinib?
Many people continue to work and travel on osimertinib, particularly once any early side effects have settled. Tiredness and loose motions are the most common things that can affect daily activity in the first weeks, and most people find these manageable. Before a long-haul flight, ask your oncologist — prolonged immobility raises clot risk for people with cancer generally, and your team can advise whether any precautions are needed. Driving is not typically restricted, but rest before driving if you feel very fatigued.
How long will I take osimertinib for?
There is no fixed course length. NCCN and ESMO guidelines support continuing osimertinib for as long as it is controlling the cancer and the side effects are tolerable. How long that means in practice varies from person to person. Your oncologist will review the benefit of continuing at each follow-up, and that review is ongoing rather than based on a fixed end date. The aim throughout is to maintain quality of life alongside disease control.
Is osimertinib available in India and what does it cost?
Yes. Osimertinib is approved by CDSCO and available in India under the brand name Tagrisso. Whether your health insurance covers it depends on your specific policy — confirm this with your insurer before starting. Costs can be substantial, and patient assistance programmes exist that your oncology team can help you explore. Some state government schemes in Telangana and Andhra Pradesh offer support for certain cancer medicines — your CION team can advise on what currently applies in your area.